Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26. https://doi.org/10.1056/NEJMra052638

Article  CAS  PubMed  Google Scholar 

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33. https://doi.org/10.1016/j.bbmt.2009.07.004.

Article  Google Scholar 

Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, et al. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Transpl. 2011;17:1505–11. https://doi.org/10.1016/j.bbmt.2011.02.011.

Article  CAS  Google Scholar 

Spyridonidis A, Labopin M, Savani B, Giebel S, Bug G, Schönland S, et al. Reduced 8-gray compared to standard 12-gray total body irradiation for allogeneic transplantation in first remission acute lymphoblastic leukemia: a study of the acute leukemia working party of the EBMT. Hemasphere. 2023;7:e812. https://doi.org/10.1097/hs9.0000000000000812.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gagelmann N, Kroger N. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021? Haematologica. 2021;106:1794–804. https://doi.org/10.3324/haematol.2020.268839.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55:1114–25. https://doi.org/10.1038/s41409-020-0803-y.

Article  CAS  Google Scholar 

Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood. 2008;112:415–25. https://doi.org/10.1182/blood-2007-08-104745.

Article  CAS  PubMed  Google Scholar 

Hirschbuhl K, Labopin M, Polge E, Blaise D, Bourhis JH, Socie G, et al. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2023;58:874–80. https://doi.org/10.1038/s41409-023-01966-w.

Article  CAS  Google Scholar 

Giebel S, Labopin M, Sobczyk-Kruszelnicka M, Stelljes M, Byrne JL, Fegueux N, et al. Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2021;56:481–91. https://doi.org/10.1038/s41409-020-01050-7.

Article  CAS  Google Scholar 

Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395:1146–62. https://doi.org/10.1016/S0140-6736(19)33018-1

Article  CAS  PubMed  Google Scholar 

Malard F, Chevallier P, Guillaume T, Delaunay J, Rialland F, Harousseau JL, et al. Continuous reduced nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a single-institution’s three decade experience. Biol Blood Marrow Transpl. 2014;20:1217–23. https://doi.org/10.1016/j.bbmt.2014.04.021.

Article  Google Scholar 

Peric Z, Labopin M, Peczynski C, Polge E, Cornelissen J, Carpenter B, et al. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT. Bone Marrow Transpl. 2020;55:1560–9. https://doi.org/10.1038/s41409-020-0878-5.

Article  CAS  Google Scholar 

Jain T, Alahdab F, Firwana B, Sonbol MB, Almader-Douglas D, Palmer J. Choosing a reduced-intensity conditioning regimen for allogeneic stem cell transplantation, fludarabine/busulfan versus fludarabine melphalan: a systematic review and meta-analysis. Biol Blood Marrow Transpl. 2019;25:728–33. https://doi.org/10.1016/j.bbmt.2018.11.016.

Article  CAS  Google Scholar 

Yoon JH, Min GJ, Park SS, Jeon YW, Lee SE, Cho BS, et al. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. Cancer. 2019;125:873–83. https://doi.org/10.1002/cncr.31874.

Article  CAS  PubMed  Google Scholar 

Eom KS, Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol. 2013;88:634–41. https://doi.org/10.1002/ajh.23465.

Article  CAS  PubMed  Google Scholar 

Lee S, Kim DW, Cho BS, Yoon JH, Shin SH, Yahng SA, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012;26:2367–74. https://doi.org/10.1038/leu.2012.164.

Article  CAS  PubMed  Google Scholar 

Yoon JH, Yhim HY, Kwak JY, Ahn JS, Yang DH, Lee JJ, et al. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Oncol. 2016;27:1081–8. https://doi.org/10.1093/annonc/mdw123

Article  PubMed  Google Scholar 

Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer Med. 2019;8:7650–9. https://doi.org/10.1002/cam4.2680.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoon SY, Yoon JH, Min GJ, Park SS, Park S, Lee SE, et al. Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2020;55:1469–72. https://doi.org/10.1038/s41409-019-0708-9.

Article  Google Scholar 

Lee SH, Yoon JH, Min GJ, Park SS, Park S, Lee SE, et al. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study. Int J Hematol. 2022;115:135–9. https://doi.org/10.1007/s12185-021-03231-6.

Article  CAS  PubMed  Google Scholar 

Yoon JH, Kwag D, Lee JH, Min GJ, Park SS, Park S, et al. Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score-matched cohort analysis. Ther Adv Hematol. 2023;14:20406207231154713 https://doi.org/10.1177/20406207231154713.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439–43. https://doi.org/10.1182/blood-2010-02-266551.

Article  CAS  PubMed  Google Scholar 

Kawamura K, Kako S, Mizuta S, Ishiyama K, Aoki J, Yano S, et al. Comparison of conditioning with fludarabine/busulfan and fludarabine/melphalan in allogeneic transplantation recipients 50 years or older. Biol Blood Marrow Transpl. 2017;23:2079–87. https://doi.org/10.1016/j.bbmt.2017.09.003.

Article  CAS  Google Scholar 

Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission. Bone Marrow Transpl. 2021;56:828–40. https://doi.org/10.1038/s41409-020-01097-6.

Article  Google Scholar 

Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. Nat Rev Dis Prim. 2023;9:27 https://doi.org/10.1038/s41572-023-00438-1.

Article  PubMed  Google Scholar 

Velardi E, Tsai JJ, van den Brink MRM. T cell regeneration after immunological injury. Nat Rev Immunol. 2021;21:277–91. https://doi.org/10.1038/s41577-020-00457-z.

Article  CAS  PubMed  Google Scholar 

Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, et al. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2024;59:217–23. https://doi.org/10.1038/s41409-023-02139-5.

Article  CAS  Google Scholar 

Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia. 2007;21:2109–16.